Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Enbumyst
Synonyms :
Bumetanide Intranasal
Class :
Loop diuretics
Brand Name :
Enbumyst
Synonyms :
Bumetanide Intranasal
Class :
Loop diuretics
ADULT DOSING
Dosage Forms & Strengths
A unit-dose nasal spray formulation with 0.5 mg/0.1 mL per actuation
Approved for the management of edema related to congestive heart failure, hepatic disease, or renal conditions such as nephrotic syndrome Typical starting dose is 0.5-2 mg administered one time daily Dosage should be tailored to the patient’s response, not exceeding 2 mg a day Therapy is not intended for long-term use and should be transitioned to oral diuretics when feasible
Safety and efficacy are not established
Refer to adult dosing
The drug inhibits sodium and chloride reabsorption in the proximal tubule, distal tubule, and loop of Henle, resulting in a significant diuretic effect. Its action in the distal tubule is independent of inhibition of carbonic anhydrase or antagonism of aldosterone.
Frequency Defined
<1%
Hypotension (0.8%)
Nausea (0.6%)
Encephalopathy (with pre-existing liver disease) (0.6%)
1-10%
Hypovolemia (4.8%)
Headache (0.6-3%)
Muscle cramps (1.1%)
Dizziness (1.1%)
Frequency not defined
General disorders and administration site conditions: Fatigue, weakness.
Gastrointestinal disorders: Abdominal pain, diarrhea, dry mouth, GI upset, vomiting.
Ear and labyrinth disorders: Ear discomfort, impaired hearing, vertigo.
Cardiac disorders: Chest pain, electrocardiogram changes.
Blood and lymphatic system disorders: Deviations in hemoglobin, prothrombin time, haematocrit, WBC and differential counts, thrombocytopenia.
None
Contraindication/Caution:
Contraindication
History of hypersensitivity reaction to bumetanide
Hepatic coma
Anuria
Cautions
Drug interactions
Fluid, electrolyte, and metabolic abnormalities
Ototoxicity
Worsening renal function
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion in human breastmilk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
The drug inhibits sodium and chloride reabsorption in the proximal tubule, distal tubule, and loop of Henle, resulting in a significant diuretic effect. Its action in the distal tubule is independent of inhibition of carbonic anhydrase or antagonism of aldosterone.
Pharmacokinetics:
Absorption
The drug is rapidly absorbed, reaching peak plasma concentrations in about one hour.
Distribution
It is extensively distributed in the body, with 94-96% bound to plasma proteins.
Metabolism
Metabolism occurs primarily through oxidation of the N-butyl side chain, leading to identifiable metabolites.
Excretion and Elimination
The elimination half-life is approximately three hours. Excretion takes place mainly via the urine (81%, with 45% excreted unchanged) and to a smaller extent through bile (about 2%).
For intranasal administration only. Each spray unit can only be used once. Do not prime the device or reuse it after a single dose. The spray should be aimed into the nasal cavity, ensuring it does not come to direct contact with the nasal wall. If the prescribed dose requires more than one spray, alternate between the right and left nostril.
Patient information leaflet
Generic Name: bumetanide intranasal
Why do we use bumetanide intranasal?
Bumetanide nasal spray features a novel formulation of the loop diuretic bumetanide that is delivered intranasally. The bumetanide nasal spray serves as a quick-acting alternative to oral and intravenous (IV) diuretics, especially edema caused by heart failure, liver disease, kidney disease, and nephrotic syndrome.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
